Dengue Fever

Clinical Research Centre, Hospital Kuala Lumpur

The Clinical Epidemiology of Hospitalized Dengue Cases in Malaysia

Dr. Woon Yuan Liang

Doctor

Clinical Research Centre, Malaysia

Ibuprofen 800mg IV piggyback and Saline IVP q 6 hours x 4 during uterine fibroid embolization

Acetaminophen 1 gram IV piggyback and Saline IVP q6 hours x 4 during uterine fibroid embolization

Ibuprofen 800 mg/ Acetaminophen 1 gram IV piggyback and Saline IVP 6 hours x 4 during uterine fibroid embolization

Saline/Saline IV piggyback and IVP Ketorolac 30 mg q6 hours x 4 during uterine fibroid embolization

Ibuprofen 800mg IV piggyback and Saline IVP q 6 hours x 4.
IV Ibuprofen

Intravenous Ibuprofen

Acetaminophen 1 gram IV piggyback and Saline IVP q6 hours x 4
IV Acetaminophen

Intravenous Acetaminophen

Ibuprofen 800 mg/ Acetaminophen 1 gram IV piggyback and Saline IVP 6 hours x 4
IV Ibuprofen
IV Acetaminophen

IV Ibuprofen/IV Acetaminophen

Saline/Saline IV piggyback and IVP Ketorolac 30 mg q6 hours x 4
IV Placebo

Intravenous Placebo/Intravenous Placebo

Total

Sex: Female, Male

Region of Enrollment

Primary efficacy objective is to compare the change in maximum level of pain experienced by patient over 24 hours between IV acetaminophen and IV ibuprofen (alone and in combination), and the current standard of care medication regimen. This comparison will be measured using a visual analog scale (VAS) from 0 to 10, 0 signifying no pain and 10 signifying the worst possible pain. The scores reported are the mean of all patients' VAS scores in each respective category.

Evaluation of Maximum Pain Intensity Change Over 24 Hours With the Addition of IV Acetaminophen and IV Ibuprofen

Primary efficacy objective is to compare the change in mean pain intensity score over 24 hours between IV acetaminophen and IV ibuprofen (alone and in combination), and the current standard of care medication regimen. This comparison will be measured using a visual analog scale (VAS) from 0 to 10, 0 signifying no pain and 10 signifying the worst possible pain. The scores reported are the mean of all patients' VAS scores in each respective category.

Evaluation of Mean Pain Intensity Over 24 Hours With the Addition of IV Acetaminophen and IV Ibuprofen

Assessment of mean nausea by mean of VAS scores over a 24-hour period. VAS score is measured using a scale of 0 to 10, 0 signifying no nausea and 10 signifying the worst possible nausea. The scores reported are the mean of all patients' VAS scores in each respective category.

Mean Nausea Intensity

Mean opioid consumption in morphine equivalents over 24 hours

Opioid Consumption

Mean dose of anti-emetic medication in milligrams given over 24 hours

Anti-Emetic Consumption

Assessment of maximum level of nausea experienced by patient, by mean of VAS scores over a 24-hour period. VAS score is measured using a scale of 0 to 10, 0 signifying no nausea and 10 signifying the worst possible nausea. The scores reported are the mean of all patients' VAS scores in each respective category.

Maximum Nausea Intensity

Overall Study

Director of Clinical Research

Symptomatic Uterine Fibroids and Adenomyosis

IV Ibuprofen

IV Acetaminophen

Intravenous placebo/Intravenous placebo

Ronald Reagan UCLA Medical Center

Santa Monica/UCLA Medical Center and Orthopaedic Hospital

Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure

A Prospective, Double Blind, Randomized, Placebo Controlled Study to Compare the Effectiveness of Intravenous Acetaminophen and Intravenous Ibuprofen in Reducing Post Procedural Pain in the Uterine Fibroid Embolization Procedure

Cheryl Hoffman

University of California, Los Angeles

Sponsor Name Pending

ferrous bisglycinate chelate 1 tablet daily

ferrous bisglycinate chelate 2 tablets daily

Participants received ferrous bisglycinate chelate, 1 tablet of 60 mg, once-daily after dinner, via oral route for 8 weeks.

Ferrous Bisglycinate Chelate 60 mg 1 Once-daily

Participants received ferrous bisglycinate chelate, 1 tablet each of 60 mg, twice-daily after breakfast and dinner, via oral route for 8 weeks.

Ferrous Bisglycinate Chelate 60 mg 1 Twice-daily

Participants received ferrous ascorbate, 1 tablet of 100 mg once-daily after dinner, via oral route for 8 weeks.

Ferrous Ascorbate 100 mg 1 Once-daily

At fortnightly visits, blood was collected for Hb. Baseline (Visit 0) was not more than 5 days from Week 1 or randomization. Change from Baseline was calculated by subtracting Baseline values from post-Baseline values.

Change From Baseline in Hemoglobin (Hb) After 8 Weeks of Treatment in Each Ferrous Bisglycinate Chelate Group (1 Tablet Daily and 2 Tablets Daily)

Mean Change in Hb From Baseline to 8 Weeks

At fortnightly visits, blood was collected for Hb. Number of participants who achieved a target Hb of more than or equal to 12 gm/dL is presented.

Percentage of Participants Who Achieved a Target Hb More Than or Equal to 12 gm/dL After 8 Weeks of Treatment

At fortnightly visits, blood was collected for Hb. Mean change in Hb at Week 2, Week 4, Week 6 and Week 8 are presented.

Mean Change in Hb During 8 Weeks Therapy

The comparison in percentage of participants with gastrointestinal side effects during 8 week treatment period is reported. Gastrointestinal side effects during 8 weeks treatment included abdominal discomfort, gastritis, nausea, dyspepsia, change in bowel habit, constipation, faeces discolored, diarrhea and flatulence.

Difference in Percentage of Participants With Gastrointestinal Side Effects During 8 Weeks Treatment With Ferrous Bisglycinate Chelate and Ferrous Ascorbate

GSK Response Center

Haematopoiesis

ferrous ascorbate

ferrous bisglycinate chelate 1 OD

ferrous bisglycinate chelate 2 OD

GSK Investigational Site

A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.

A Multicentre, Randomized, Laboratory-blinded, Parallel-group Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.

GlaxoSmithKline

Tranexamic acid with titrated doses. All women with menorrhagia will take .

Menorrhagia

After The starting dose of tranexamic acid will be 500 mg twice daily beginning the first day of menstrual flow for a total of 6 days per menstrual cycle. If after 2 days there is still menorrhagia without significant side effects the will be increased. The women will be assessed again at day 4 and 9 and dose escalation will continue until they have reached the optimal dose.The dose of tranexamic acid will be increased as follows: 1000 mg twice daily, 1000 mg three times daily, 1500 mg/1000 mg/1000 mg, 1000 mg four times daily, 1500 mg three times daily, and 1500 mg four times daily (maximum dose).Each patient will be followed for a minimum of one menstrual cycle and a maximum of 3 cycles.

menorrhagia/kräkning

The Clinical Epidemiology of Hospitalized Dengue Cases in Malaysia

Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure

A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.

The Assessment of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen